Product Overview

HapOnco^® mClean MRD Tests are a series of ctDNA-based NGS assays for detecting MRD in lung, gastrointestinal, hepatobiliary and pancreatic cancer patients who are unamenable to tumor-informed MRD testing. The tests utilize a tumor-naïve approach to detect MRD in patients’ liquid biopsies, based on a preselected gene panel that covers hotspot mutations in a tumor type-specific manner. Leveraging our proprietary LIUDUS^® platform with ultra-deep sequencing, HapOnco^® mClean MRD Tests are capable of detecting ultra-low-frequency MRD to inform recurrence risk for cancer patients who are unamenable to tumor-informed MRD testing.